UK markets closed
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • FTSE 250

    19,363.28
    -46.14 (-0.24%)
     
  • AIM

    854.63
    +4.07 (+0.48%)
     
  • GBP/EUR

    1.1668
    +0.0025 (+0.21%)
     
  • GBP/USD

    1.2287
    +0.0031 (+0.25%)
     
  • BTC-GBP

    13,797.37
    -88.09 (-0.63%)
     
  • CMC Crypto 200

    402.44
    +1.02 (+0.25%)
     
  • S&P 500

    4,051.97
    -24.60 (-0.60%)
     
  • DOW

    34,292.15
    -102.86 (-0.30%)
     
  • CRUDE OIL

    80.97
    -0.25 (-0.31%)
     
  • GOLD FUTURES

    1,810.00
    -5.20 (-0.29%)
     
  • NIKKEI 225

    27,777.90
    -448.18 (-1.59%)
     
  • HANG SENG

    18,675.35
    -61.09 (-0.33%)
     
  • DAX

    14,529.39
    +39.09 (+0.27%)
     
  • CAC 40

    6,742.25
    -11.72 (-0.17%)
     

Olink reports third quarter 2022 financial results

Olink Proteomics AB
Olink Proteomics AB

UPPSALA, Sweden, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter of 2022.

Highlights

  • Third quarter 2022 revenue totaled $31.8 million, representing year over year growth of 59% on a reported basis and 68% on a constant currency adjusted like-for-like basis

  • Total Explore customer installations reached 40, with 11 installations during the third quarter

  • Signature Q100 placements reached 63, with 12 additional placements during the third quarter

  • Explore revenue of $21.7 million accounted for 68% of total third quarter revenue, with Explore Kit revenue totaling $10.6 million, or 49% of total Explore revenue

  • Third quarter kits revenue and analysis services revenue represented 42% and 48% of total revenue, respectively

  • Third quarter 2022 adjusted EBITDA was ($1.7) million, with a net loss of ($1.3) million; compared to third quarter 2021 adjusted EBITDA of ($7.5) million and net loss of ($5.5) million

  • Expects full year 2022 revenue to be in the range of $138 million to $142 million; representing strong growth of 45% to 49%; with constant currency revenue expected near the top end of this range, and reported revenue expected near the bottom end of this range when including unexpected foreign currency headwinds

“The strengths of the Olink platform are clearly resonating with customers across all major proteomics use cases, and in all major therapeutic areas from high-plex to low-plex; academia, biopharma, and service providers,” said Jon Heimer, CEO of Olink. “Olink achieved additional major milestones as well, including reaching the 1,000th publication highlighting the use of PEA technology, and the launch of Olink Insight to customers and collaborators globally.”

Third quarter financial results
“Our third quarter benefited from very robust revenue growth, favorable product mix, and strong progress toward key financial objectives, even as foreign exchange headwinds were stronger than anticipated,” said Oskar Hjelm, CFO of Olink. "As we consider Olink’s future, the combination of further disciplined investment into the organization plus our strong growth prospects, should help drive our return to sustained profitability next year, and long-term value creation.”

Total revenue for the third quarter of 2022 was $31.8 million, as compared to $20.0 million for the third quarter of 2021, growing 59% year over year.

Third quarter 2022 kits revenue of $13.4 million represented 42% of total revenue, versus 26% in the second quarter. Kits yearly revenue growth of 265% was led by very strong performance from Explore.

Analysis services revenue for the third quarter of 2022 was $15.1 million, flat year-over-year.

Other revenue was $3.2 million for the third quarter of 2022, as compared to $1.2 million for the third quarter of 2021, with Signature Q100 providing the largest contribution.

By geography, revenue during the third quarter of 2022 was $12.4 million in Americas, $15.0 million in EMEA (including Sweden), and $4.4 million in China and RoW (including Japan).

Adjusted EBITDA was ($1.7) million for the third quarter of 2022, as compared to ($7.5) million for the third quarter of 2021.

Adjusted gross profit was $21.8 million in the third quarter of 2022, as compared to $13.1 million in the third quarter of 2021; and reported gross profit was $21.0 million in the third quarter of 2022, as compared to $12.4 million in the third quarter of 2021.

By segment, adjusted gross profit margin for kits was 89% for the third quarter of 2022, as compared to 91% for the third quarter of 2021; and reported gross profit margin for kits was 87% for the third quarter of 2022, as compared to 88% for the third quarter of 2021.

Third quarter 2022 adjusted gross profit margin for analysis services was 55% as compared to 59% in the third quarter of 2021; and reported gross profit margin for analysis services was 51% as compared to 55% in the third quarter of 2021. The decline in analysis services margin was driven by fulfillment of the UKB-PPP.

Third quarter 2022 adjusted gross profit margin and reported gross profit margin for Other was 49%; versus third quarter 2021 adjusted gross profit margin and reported gross profit margin of 74%.

Total operating expenses for the third quarter of 2022 were $29.0 million, as compared to $24.1 million for the third quarter of 2021. The increase was largely due to continued investment in the Company’s organization overall.

Net loss for the third quarter of 2022 was ($1.3) million, as compared to a net loss of ($5.5) million for the third quarter of 2021. Net loss per share for the third quarter of 2022 was ($0.01) based on a weighted average number of outstanding shares of 119,098,118; as compared to a net loss per share of ($0.05) in the third quarter of 2021 based on a weighted average number of outstanding shares of 119,007,062.

2022 guidance
Olink expects full year 2022 revenue to be in the range of $138 million to $142 million; representing strong growth of 45% to 49%; with constant currency revenue expected near the top end of this range, and reported revenue expected near the bottom end of this range when including unexpected foreign currency headwinds.

Webcast and conference call details
Company management will host a conference call to discuss financial results at 8:00 am ET. Investors interested in listening to the conference call are required to register online here. A live webcast will be available in the “Events” section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.

Olink investor day
On November 14th, 2022, from 11:00 am to 2:30 pm ET, Olink will host an investor day, providing direct access to key opinion leaders and collaborators from leading academic centers and industry, highlighting exciting research and development settings where Olink is a meaningful contributor. The agenda will also include Olink's perspectives on the considerable progress made in proteomics over the past year, major commercial initiatives ongoing at the Company, and our planning for continued strength in the market.

2023 annual general meeting of shareholders
Olink will hold its 2023 annual general meeting of shareholders in Uppsala, Sweden, on April 17, 2023. Shareholders are entitled to have items addressed at the annual general meeting if the request has been submitted to the Board of Directors not later than seven weeks prior to the annual general meeting.

Statement regarding use of non IFRS financial measures
We present certain non-IFRS financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We believe that the use of these non-IFRS measures facilitates investors’ assessment of our operating performance. We caution readers that amounts presented in accordance with our definitions of adjusted EBITDA, adjusted gross profit, adjusted gross profit margin, adjusted gross profit margin by segment, and constant currency revenue growth, may not be the same as similar measures used by other companies. Not all companies and Wall Street analysts calculate the non-IFRS measures we use in the same manner. We compensate for these limitations by reconciling each of these non-IFRS measures to the nearest IFRS performance measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

We are not able to forecast constant currency revenue on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting foreign currency exchange rates and, as a result, are unable to provide a reconciliation to forecasted constant currency revenue.

Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

Forward-looking statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our 2022 revenue outlook, our Explore externalizations, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the caption "Risk Factors" in our Form 20-F (Commission file number 001-40277) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections for the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

 

 

Three months ended
September 30,

 

Nine months ended
September 30,

Amounts in thousands of U.S. Dollars

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue

 

$

31,772

 

 

$

19,974

 

 

$

81,963

 

 

$

51,290

 

Cost of goods sold

 

 

(10,785

)

 

 

(7,565

)

 

 

(30,589

)

 

 

(18,384

)

Gross profit

 

 

20,987

 

 

 

12,409

 

 

 

51,374

 

 

 

32,906

 

Selling expenses

 

 

(11,240

)

 

 

(9,035

)

 

 

(31,293

)

 

 

(21,718

)

Administrative expenses

 

 

(11,998

)

 

 

(11,086

)

 

 

(40,391

)

 

 

(35,669

)

Research and development expenses

 

 

(6,443

)

 

 

(4,210

)

 

 

(19,761

)

 

 

(13,419

)

Other operating income

 

 

725

 

 

 

276

 

 

 

1,292

 

 

 

1,039

 

Operating loss

 

 

(7,969

)

 

 

(11,646

)

 

 

(38,779

)

 

 

(36,861

)

Interest, net

 

 

(112

)

 

 

(57

)

 

 

(367

)

 

 

(2,010

)

Foreign exchange, net

 

 

6,427

 

 

 

4,853

 

 

 

16,906

 

 

 

(648

)

Other financial expenses

 

 

-

 

 

 

18

 

 

 

-

 

 

 

(1,738

)

Loss before tax

 

 

(1,654

)

 

 

(6,832

)

 

 

(22,240

)

 

 

(41,257

)

Income tax benefit

 

 

366

 

 

 

1,361

 

 

 

3,960

 

 

 

10,890

 

Net loss for the period
(Attributable to shareholders of the Parent)

 

$

(1,288

)

 

$

(5,471

)

 

$

(18,280

)

 

$

(30,367

)

Basic and diluted loss per share

 

$

(0.01

)

 

$

(0.05

)

 

$

(0.15

)

 

$

(0.37

)

 

 

 

 

 

 

 

 

 

Other comprehensive (loss)/income:

 

 

 

 

 

 

 

 

Items that may be reclassified to profit or loss:

 

 

 

 

 

 

 

 

Exchange differences from translation of foreign operations

 

 

(31,989

)

 

 

(16,703

)

 

 

(84,378

)

 

 

(24,089

)

Other comprehensive (loss)/income for the period, net of tax

 

 

(31,989

)

 

 

(16,703

)

 

 

(84,378

)

 

 

(24,089

)

Total comprehensive (loss)/income for the period, net of tax

 

 

(33,277

)

 

 

(22,174

)

 

 

(102,658

)

 

 

(54,456

)

Total comprehensive (loss)/income for the period
(Attributable to shareholder of the Parent)

 

$

(33,277

)

 

$

(22,174

)

 

$

(102,658

)

 

$

(54,456

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)

Amounts in thousands of U.S. Dollars

 

As of
September 30,
2022

 

As of
December 31,
2021

ASSETS

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

 

 

243,257

 

 

 

308,124

 

Property, plant and equipment

 

 

13,409

 

 

 

12,696

 

Right-of-use asset

 

 

9,608

 

 

 

8,778

 

Deferred tax assets

 

 

12,106

 

 

 

9,091

 

Other long-term receivables

 

 

347

 

 

 

422

 

Total non-current assets

 

$

278,727

 

 

$

339,111

 

Current assets

 

 

 

 

Inventories

 

 

35,742

 

 

 

28,940

 

Trade receivables

 

 

30,088

 

 

 

42,061

 

Other receivables

 

 

7,277

 

 

 

4,094

 

Prepaid expenses and accrued income

 

 

9,200

 

 

 

7,476

 

Cash at bank and in hand

 

 

77,126

 

 

 

118,096

 

Total current assets

 

$

159,433

 

 

$

200,667

 

TOTAL ASSETS

 

$

438,160

 

 

$

539,778

 

EQUITY

 

 

 

 

Share capital

 

 

30,988

 

 

 

30,964

 

Other contributed capital

 

 

511,867

 

 

 

506,008

 

Reserves/(Deficit)

 

 

(82,670

)

 

 

1,701

 

Accumulated losses

 

 

(81,284

)

 

 

(62,997

)

Total equity attributable to shareholders of the Parent

 

$

378,901

 

 

$

475,676

 

LIABILITIES

 

 

 

 

Non-current liabilities

 

 

 

 

Lease liabilities

 

 

6,764

 

 

 

5,427

 

Deferred tax liabilities

 

 

21,427

 

 

 

27,092

 

Total non-current liabilities

 

$

28,191

 

 

$

32,519

 

Current liabilities

 

 

 

 

Lease liabilities

 

 

2,355

 

 

 

2,952

 

Accounts payable

 

 

10,422

 

 

 

8,668

 

Current tax liabilities

 

 

1,419

 

 

 

314

 

Other current liabilities

 

 

16,872

 

 

 

19,649

 

Total current liabilities

 

$

31,068

 

 

$

31,583

 

Total liabilities

 

$

59,259

 

 

$

64,102

 

TOTAL EQUITY AND LIABILITIES

 

$

438,160

 

 

$

539,778

 

 

 

 

 

 

 

 

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

 

 

Nine months ended
September 30,

Amounts in thousands of U.S. Dollars

 

 

2022

 

 

2021

 

 

 

 

 

 

 

 

 

Operating activities

 

 

 

 

 

 

 

Loss before tax

 

$

(22,240

)

$

(41,257

)

Adjustments reconciling loss before tax to operating cash flows:

 

 

 

Depreciation and amortization

 

 

13,034

 

 

11,176

 

Net finance expense/(income)

 

 

(16,425

)

 

4,396

 

Loss on sale of assets

 

 

401

 

 

36

 

Share-based compensation expense

 

 

5,826

 

 

636

 

Other

 

 

(94

)

 

-

 

Changes in working capital:

 

 

 

(Increase) in inventories

 

 

(13,194

)

 

(6,723

)

Decrease in accounts receivable

 

 

7,738

 

 

9,194

 

Decrease/(Increase) in other current receivables

 

 

(6,435

)

 

(8,804

)

Increase/(Decrease) in trade payables

 

 

3,281

 

 

(1,041

)

(Decrease) in other current liabilities

 

 

(555

)

 

(1,821

)

Interest received

 

 

40

 

 

-

 

Interest paid

 

 

(407

)

 

(2,192

)

Tax paid

 

 

(937

)

 

(2,618

)

Cash flow used in operating activities

 

$

(29,967

)

$

(39,018

)

Investing activities

 

 

 

Purchase of intangible assets

 

 

(1,060

)

 

(4,338

)

Purchase of property, plant and equipment

 

 

(5,115

)

 

(4,784

)

Proceeds from sale of property, plant and equipment

 

 

-

 

 

145

 

Decrease/(Increase) in other non-current financial assets

 

 

56

 

 

(301

)

Cash flow used in investing activities

 

$

(6,119

)

$

(9,278

)

Financing activities

 

 

 

Proceeds from issue of share capital

 

 

24

 

 

264,706

 

Share issue costs

 

 

-

 

 

(19,484

)

Proceeds from interest-bearing loans and borrowings

 

 

-

 

 

2,311

 

Repayment of interest-bearing loans and borrowings

 

 

-

 

 

(65,627

)

Payment of principal portion of lease liability

 

 

(2,144

)

 

(1,952

)

Cash flow (used in)/from financing activities

 

$

(2,120

)

$

179,954

 

Net cash flow during the period

 

 

(38,206

)

 

131,658

 

Cash at bank and in hand at the beginning of the period

 

 

118,096

 

 

8,655

 

Net foreign exchange difference

 

 

(2,764

)

 

(157

)

Cash at bank and in hand at the end of the period

 

$

77,126

 

$

140,156

 

 

 

 

 

 

 

 

 

Reconciliations of adjusted gross profit to gross profit, the most directly comparable IFRS measure, by segment (unaudited):

 

 

Three months ended
September 30,

 

Nine months ended
September 30,

Amounts in thousands of U.S. Dollars unless otherwise stated

 

 

2022

 

 

2021

 

 

 

2022

 

 

2021

 

Kit

 

 

 

 

 

 

Revenue

 

 

13,395

 

 

3,668

 

 

 

24,535

 

 

11,534

 

Cost of goods sold

 

 

(1,696

)

 

(456

)

 

 

(3,120

)

 

(1,673

)

Kit Gross Profit

 

$

11,699

 

$

3,212

 

 

$

21,415

 

$

9,861

 

Kit Gross Profit %

 

 

87.3

%

 

87.6

%

 

 

87.3

%

 

85.5

%

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

Depreciation charges

 

 

142

 

 

116

 

 

 

410

 

 

317

 

Share-based compensation expenses

 

 

42

 

 

-

 

 

 

122

 

 

-

 

Kit Adjusted Gross Profit

 

$

11,883

 

$

3,328

 

 

$

21,947

 

$

10,178

 

Kit Adjusted Gross Profit %

 

 

88.7

%

 

90.7

%

 

 

89.5

%

 

88.2

%

 

 

 

 

 

 

 

Service

 

 

 

 

 

 

Revenue

 

 

15,132

 

 

15,123

 

 

 

49,623

 

 

36,528

 

Cost of goods sold

 

 

(7,444

)

 

(6,806

)

 

 

(23,369

)

 

(15,473

)

Service Gross Profit

 

$

7,688

 

$

8,317

 

 

$

26,254

 

$

21,055

 

Service Gross Profit %

 

 

50.8

%

 

55.0

%

 

 

52.9

%

 

57.6

%

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

Depreciation charges

 

 

605

 

 

575

 

 

 

1,888

 

 

1,575

 

Share-based compensation expenses

 

 

23

 

 

-

 

 

 

112

 

 

-

 

Service Adjusted Gross Profit

 

$

8,316

 

$

8,892

 

 

$

28,254

 

$

22,630

 

Service Adjusted Gross Profit %

 

 

55.0

%

 

58.8

%

 

 

56.9

%

 

62.0

%

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

Revenue

 

 

3,245

 

 

1,183

 

 

 

7,805

 

 

3,228

 

Cost of goods sold

 

 

(1,645

)

 

(303

)

 

 

(4,100

)

 

(1,238

)

Gross Profit

 

$

1,600

 

$

880

 

 

$

3,705

 

$

1,990

 

Gross Profit %

 

 

49.3

%

 

74.4

%

 

 

47.5

%

 

61.6

%

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

Depreciation charges

 

 

-

 

 

-

 

 

 

-

 

 

-

 

Share-based compensation expenses

 

 

-

 

 

-

 

 

 

-

 

 

-

 

Other Adjusted Gross Profit

 

$

1,600

 

$

880

 

 

$

3,705

 

$

1,990

 

Other Adjusted Gross Profit %

 

 

49.3

%

 

74.4

%

 

 

47.5

%

 

61.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of constant currency revenue growth to revenue growth as reported under IFRS, the most directly comparable IFRS measure (unaudited):

We use the non-IFRS measure of constant currency growth, which we define as our total revenue growth from one fiscal year to the next on a constant currency exchange rate basis. We measure our constant currency revenue growth by applying the current fiscal period’s average exchange rate to the prior year fiscal period.

 

 

Three months ended
September 30,

Amounts in thousands of U.S. Dollars

 

 

2022

 

 

 

2021

 

Revenue

 

$

31,772

 

 

$

19,974

 

Revenue growth (IFRS)

 

 

59

%

 

 

 

Foreign exchange impact

 

 

-9

%

 

 

 

Constant currency revenue growth

 

 

68

%

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of consolidated adjusted gross profit to gross profit, the most directly comparable IFRS measure (unaudited):

 

 

Three months ended
September 30

 

Nine months ended
September 30,

Amounts in thousands of U.S. Dollars unless otherwise stated

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue

 

 

31,772

 

 

 

19,974

 

 

 

81,963

 

 

$

51,290

 

Cost of goods sold

 

 

(10,785

)

 

 

(7,565

)

 

 

(30,589

)

 

 

(18,384

)

Consolidated Gross Profit

 

$

20,987

 

 

$

12,409

 

 

$

51,374

 

 

$

32,906

 

Consolidated Gross Profit %

 

 

66.1

%

 

 

62.1

%

 

 

62.7

%

 

 

64.2

%

 

 

 

 

 

 

 

 

 

Less:

 

 

 

 

 

 

 

 

Depreciation charges

 

 

748

 

 

 

691

 

 

 

2,298

 

 

 

1,892

 

Share-based compensation expenses

 

 

65

 

 

 

-

 

 

 

234

 

 

 

-

 

Consolidated Adjusted Gross Profit

 

$

21,800

 

 

$

13,100

 

 

$

53,906

 

 

$

34,798

 

Consolidated Adjusted Gross Profit %

 

 

68.6

%

 

 

65.6

%

 

 

65.8

%

 

 

67.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of adjusted EBITDA to operating loss, the most directly comparable IFRS measure (unaudited):

 

 

Three months ended
September 30,

 

Nine months ended
September 30,

Amounts in thousands of U.S. Dollars

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Operating (loss)

 

 

(7,969

)

 

 

(11,646

)

 

 

(38,779

)

 

 

(36,861

)

Add:

 

 

 

 

 

 

 

 

Amortization

 

 

2,708

 

 

 

2,650

 

 

 

8,530

 

 

 

8,098

 

Depreciation

 

 

1,532

 

 

 

1,106

 

 

 

4,504

 

 

 

3,078

 

EBITDA

 

 

(3,729

)

 

 

(7,890

)

 

 

(25,745

)

 

 

(25,685

)

Management adjustments

 

 

189

 

 

 

39

 

 

 

990

 

 

 

7,861

 

Share-based compensation

 

 

1,808

 

 

 

335

 

 

 

5,962

 

 

 

636

 

Adjusted EBITDA

 

$

(1,732

)

 

$

(7,516

)

 

$

(18,793

)

 

$

(17,188

)